A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Donanemab
Related studies linked through entity extraction aliases.
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Alzheimer's Tau Platform: Regimen A - AADvac1
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
- Status
- RECRUITING
- Phase
- N/A
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Donanemab (LY3002813) in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Donanemab (LY3002813) in Healthy Chinese Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
- Status
- COMPLETED
- Phase
- PHASE3
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
- Status
- COMPLETED
- Phase
- PHASE2